Question

a client with leukemia is being treated with a combination of antineoplastics, including methotrexate. the client's most recent laboratory results indicate the client is experiencing bone marrow suppression. what is the nurse's priority action?

Answer 1

The nurse should immediately report the laboratory findings of bone marrow suppression to the healthcare provider, as it may necessitate adjustments in the chemotherapy regimen or supportive treatments to manage the condition.

Step-by-step explanation:

The nurse's priority action for a client with leukemia experiencing bone marrow suppression from antineoplastics, including methotrexate, is to immediately report the laboratory findings to the healthcare provider.

Bone marrow suppression is a serious adverse effect of cancer chemotherapy that can lead to a decrease in the production of white blood cells, red blood cells, and platelets, which increases the risk of infection, anemia, and bleeding. The treatment plan may need to be altered, which could include pausing or adjusting the chemotherapy dose, or administering supportive treatments such as growth factor therapy or transfusions.

For patients undergoing chemotherapy, labs such as the absolute neutrophil count (ANC) are essential to determine treatment suitability. An ANC of 1900 cells per microliter is considered within the acceptable range for many chemotherapy protocols. On the other hand, a bone marrow transplant may be indicated for patients with severe marrow damage who require recovery of bone marrow function, commonly associated with leukemia treatment.